Navigation Links
Lupin Receives FDA Approval for Generic LYRICA(R)

MUMBAI and BALTIMORE, July 5, 2012 /PRNewswire/ --

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received final approval for its Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg from the United States Food and Drugs Administration (FDA) to market a generic version of C.P. Pharmaceuticals C.V., LYRICA® (Pregabalin) capsules.

Lupin's Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg are the AB-rated generic equivalent of LYRICA® capsules, which is indicated for neuropathic pain associated with diabetic peripheral neuropathy, post herpetic neuralgia, adjunctive therapy for adult patients with partial onset seizures and fibromyalgia.

LYRICA® Capsules had annual U.S sales of approximately $1.8 billion for the twelve months ending March 2012 (IMS Health Sales Data).

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing a wide range of generic and branded formulations and APIs. The Company today has significant presence in the Cardiovascular, Diabetology, Asthma, Paediatrics, CNS, GI, Anti-Infective and NSAID space in addition to holding global leadership positions in the Anti-TB and Cephalosporin segments.

Lupin is the 5th largest and fastest growing generics player in the US (5.3% market share by prescriptions, IMS Health), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical player in India, Japan and South Africa (IMS).

For the financial year ended March 2012, Lupin's Consolidated Revenues and Profit after Tax were Rs.70,829 Million (USD 1.42 Billion) and Rs. 8,676 Million (USD 190 million) respectively. Please visit for more information.

Lupin Pharmaceuticals, Inc. is the wholly owned U.S. subsidiary of Lupin Limited.  Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit

For further information or queries, please contact - Shamsher Gorawara Head - Corporate Communications Lupin Limited: Ph: +91-98-20-338-555 Email:

Safe Harbor Statement

*LYRICA® is a registered trademark of C.P. Pharmaceuticals, C.V. a wholly owned subsidiary of Pfizer, Inc.

SOURCE Lupin Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. UCSB professor receives award for graphene electronics research
2. Watsons Generic Yaz(R) Receives FDA Approval
3. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
4. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
5. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
6. Intimate Bridge 2 Conception, Inc. Receives $4.3M
7. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
8. BioNeutral Group Receives $400,000 in Equity Financing
9. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
10. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
11. Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015  Cepheid (Nasdaq: ... ending September 30, 2015. --> ... total revenue for the third quarter of 2015 is ... per share is expected to be approximately $(0.32) for ... non-GAAP net loss per share for the third quarter ...
(Date:10/13/2015)... ... October 13, 2015 , ... InSphero AG , the ... cell culture models, has launched a 14 Day Hepatotoxicity Testing Service ... Human Liver Microtissues. The service streamlines toxicity testing of compounds in InSphero’s ...
(Date:10/13/2015)... DUBLIN , Oct. 13 2015 Research ... the "US & Europe Markets for Bone Morphogenetic ... report to their offering. --> ... factors that induce the formation of bone after a ... during embryonic development in the formation of the skeleton. ...
(Date:10/13/2015)... -- " Microbiology Culture Market - Global Industry ... " , the global microbiology culture market was valued ... bn by 2023, expanding at a CAGR of 5.9% during the ... Microbiology Culture Market - Global Industry Analysis, Size, Share, Growth, Trends, ... global microbiology culture market was valued at US$4.51 bn in 2014 ...
Breaking Biology Technology:
(Date:9/28/2015)... , September 28, 2015 According ... (Hardware & Software), Product (Scanner & Others), Application (Access ... Defense, & Others) & Geography Global - Forecast to ... to reach USD 3627.90 Million by 2020, at a ... Browse 65 market data T ables and ...
(Date:9/24/2015)... 24, 2015 Publiceringsförbud ... Kerv ( ), ... idag världens första kontaktlösa betalningsring på ... 000 GBP för massproduktion via crowdfunding.  ... , Kerv-bärare kan göra direkta ...
(Date:9/10/2015)... , Sept. 10, 2015 Pursuant ... Clinic Wellness to create an interactive, image-based health ... health and wellness kiosk.  The unique assessment quantifies ... a number that suggests an individual,s biological age ... values as measured by the kiosk. ...
Breaking Biology News(10 mins):